2126 fundamentals
JW (CAYMAN) THERAPEUTICS CO. LTD financial statements, including revenue, expenses, profit, and loss
The total revenue of 2126 for the last semiannual is 93.03 M HKD, and it's 6.24% lower compared to the previous semiannual. The net income of H2 23 is -418.72 M HKD.
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
TTM